These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37549067)

  • 1. One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations.
    Lucas F; Lewis J; Grandoni J; Sylvester KW; Bernier TD; Ting C; Sek R; Ballard K; Connors JM; Battinelli EM
    Am J Clin Pathol; 2023 Dec; 160(6):571-584. PubMed ID: 37549067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
    Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
    Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study of clinical settings, indications and consequences of measurement of direct oral anticoagulant plasma levels in Northern Tasmania, Australia.
    Lim MS; Mohamed M
    Intern Med J; 2024 Jun; 54(6):932-940. PubMed ID: 38213182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
    Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B
    J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
    Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
    Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
    Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
    Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding.
    Grottke O; Afshari A; Ahmed A; Arnaoutoglou E; Bolliger D; Fenger-Eriksen C; von Heymann C
    Eur J Anaesthesiol; 2024 May; 41(5):327-350. PubMed ID: 38567679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
    Platton S; Hunt C
    Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin complex concentrates for the urgent reversal of apixaban and rivaroxaban: an Australian retrospective cohort study.
    Wallwork S; Wang Y; Chaiwatanatorn K; Cole-Sinclair M
    Intern Med J; 2023 May; 53(5):803-811. PubMed ID: 34779569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
    Levy JH
    Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-Calibrated Anti-Factor Xa Assay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and Edoxaban.
    Ahn HS; Chae H; Kim Y; Lee HK; Kim H
    Clin Lab; 2024 Sep; 70(9):. PubMed ID: 39257123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system.
    Jakowenko N; Nguyen S; Ruegger M; Dinh A; Salazar E; Donahue KR
    Thromb Res; 2020 Dec; 196():276-282. PubMed ID: 32947066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study.
    Cavaillez T; Weinmann L; Mouton C; Delassasseigne C; Sesay M; Biais M; James C; Roullet S
    Thromb Res; 2021 Oct; 206():76-83. PubMed ID: 34419866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.